Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Dendreon Corporation    

End-of-day quote. End-of-day quote  - 06/11
0.0325 USD   -4.41%
2015DJValeant Approved to Buy Dendreon Assets for $495 Million
2015 Drugmaker Valeant close to buying Salix - source
2015 VALEANT SECURES : Bloomberg
 SummaryChartsNewsCalendarCompanyFinancials 
Company
Dendreon Corp. discovers, develops and commercializes novel products for the treatment of cancer.The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy ACI product candidates designed to stimulate an immune response in a... 
More about the company
Latest news on DENDREON CORPORATION
2015DJValeant Approved to Buy Dendreon Assets for $495 Million
2015 Drugmaker Valeant close to buying Salix - source
2015 VALEANT SECURES FINANCING FOR POTENT : Bloomberg
2015DJEnergy Future Fights for Control of its Bankruptcy -- Week Ahead
2015 DENDREON : Valeant to buy Dendreon's prostate cancer vaccine Provenge
2014 DENDREON CORPORATION : A New Combined Approach to Cancer Immunotherapy is Needed
2014 DENDREON CORPORATION : Bankruptcies, Breakouts, and Busts; What's Happening in B..
2014DJMARKET SNAPSHOT : U.S. Stocks Eke Out Monday Gains; S&P 500, Dow Hit Records
2014DJMARKET SNAPSHOT : U.S. Stocks Eke Out Monday Gains; S&P 500, Dow Hit Records
2014DJMARKET SNAPSHOT : U.S. Stocks Eke Out Monday Gains; S&P 500, Dow Hit Records
More news
Sector news : Biotechnology & Medical Research - NEC
02/16 How Sanofi lost out to J&J in $30 billion battle for Actelion
02/14 Gilead challenges GSK with strong HIV drug data
02/13 TEVA PHARMACEUTICAL INDUSTRIES : seeks CEO with pharma background to lead recove..
02/09DJAppeals Court Allows Sanofi, Regeneron to Continue Selling Cholesterol Drug
02/08 Weak pound buoys GSK but drugmaker warns on 2017 generic threat
More sector news : Biotechnology & Medical Research - NEC
Advertisement
Chart DENDREON CORPORATION
Duration : Period :
Dendreon Corporation Technical Analysis Chart | US24823Q1076 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Managers
NameTitle
Craig R. Jalbert President, Secretary, Treasurer & Director
William Monteith Executive Vice President-Technical Operations
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
DENDREON CORPORATION-55.48%0
INCYTE CORPORATION20.17%22 822
QUINTILES IMS HOLDINGS..0.92%18 894
CELLTRION, INC.--.--%10 747
LONZA GROUP AG1.87%10 368
SEATTLE GENETICS, INC.24.12%9 272
More Results